News >

Immunotherapy Data Lead Lung Cancer Landscape Following ASCO 2018

Brandon Scalea
Published: Wednesday, Aug 15, 2018

Apar Kishor Ganti, MD

Apar Kishor Ganti, MD

Immunotherapy has risen to the forefront of thoracic oncology; however, challenges exist with comparing checkpoint inhibitors and how to best select patients for this class of agents, whether alone or in combination. This is a good problem to have, according to Apar Kishor Ganti, MD.

on A Summer of Progress: Updates from ASCO 2018, Ganti discussed some of the most intriguing abstracts in lung cancer recently presented.

OncLive®: What are some of the major updates in lung cancer research?

Ganti: There have been a lot of exciting changes in the management of patients with lung cancer over the past year. The biggest change has been the increasing use of immunotherapy, mainly the checkpoint inhibitors such as pembrolizumab and atezolizumab. A lot of exciting data have been presented in the last several months, whether at the 2018 ASCO Annual Meeting or other [meetings]. What I spoke about was a summary of some of those abstracts.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication